Tuberculosis Due to Mycobacterium bovis after Alemtuzumab Administration

We describe a patient with relapsing B chronic lymphocytic leukemia who developed systemic bacille Calmette-Guérin infection (BCGitis) after administration of alemtuzumab (Campath-1H).

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2003-07, Vol.37 (2), p.e27-e28
Main Authors: Abad, S., Gyan, E., Moachon, L., Bouscary, D., Sicard, D., Dreyfus, F., Blanche, P.
Format: Article
Language:English
Subjects:
Aged
Alemtuzumab
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm - administration & dosage
Antibodies, Neoplasm - adverse effects
Antibodies, Neoplasm - therapeutic use
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Male
Mycobacterium bovis
Tuberculosis - etiology
Tuberculosis - microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe a patient with relapsing B chronic lymphocytic leukemia who developed systemic bacille Calmette-Guérin infection (BCGitis) after administration of alemtuzumab (Campath-1H).
ISSN:1058-4838
1537-6591
DOI:10.1086/375690